NYSEARCA:XBI SPDR S&P Biotech ETF (XBI) Price, Holdings, & News → Crypto Market Preps For Trillions Worth of Inflows! (From Crypto 101 Media) (Ad) Free XBI Stock Alerts $94.89 -0.02 (-0.02%) (As of 04:10 PM ET) Add Compare Share Share Today's Range$94.06▼$95.8950-Day Range$87.06▼$102.9352-Week Range$63.80▼$103.52Volume10.25 million shsAverage Volume11.77 million shsMarket Capitalization$7.28 billionAssets Under Management$7.54 billionDividend YieldN/ANet Expense Ratio0.35% Stock AnalysisStock AnalysisChartHeadlinesHoldingsOwnershipRatingsStock AnalysisChartHeadlinesHoldingsOwnershipRatings Get SPDR S&P Biotech ETF alerts: Email Address About SPDR S&P Biotech ETF (NYSEARCA:XBI)SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges. The Biotech Index is a modified equal weight index. SSgA Funds Management, Inc. is the Fund's investment advisor.Read More XBI Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart XBI ETF News HeadlinesMarch 28, 2024 | msn.com2 Top Biotech Buyout CandidatesMarch 27, 2024 | investorplace.com3 Biotech Stocks to Buy on the Dip: March 2024March 28, 2024 | Insiders Exposed (Ad)This consistently signaled gains of 453%... 610%... and even 1036%...It doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.March 19, 2024 | investorplace.com3 Biotech ETFs Overdue for a BounceFebruary 29, 2024 | msn.comBiotech Stocks Are on a Tear. They Could Keep Climbing.February 28, 2024 | wsj.comHeard on the Street Recap: Zooming UpFebruary 13, 2024 | reuters.comSpdr S&P Biotech EtfFebruary 10, 2024 | investing.comXBI ETF Stock Price HistoryMarch 28, 2024 | Crypto 101 Media (Ad)SHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. February 3, 2024 | finance.yahoo.comSPDR S&P Biotech ETF (XBI)See More Headlines Receive XBI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for SPDR S&P Biotech ETF and its competitors with MarketBeat's FREE daily newsletter. Email Address Fund Details IssuerSSgA Fund NameSPDR S&P Biotech ETF Tax ClassificationRegulated Investment Company Stock ExchangeNYSEARCACurrent SymbolNYSEARCA:XBI Inception Date1/31/2006 Fund ManagerMichael Feehily, Karl Schneider, Raymond Donofrio Webwww.spdrs.com Phone+1-866-7872257Fund Focus Asset ClassEquity BenchmarkS&P Biotech Index CategorySector FocusHealth Care Development LevelDeveloped Markets RegionNorth America Number of Holdings139 Fund Statistics Assets Under Management$7.54 billion Average Daily Volume$12.48 million Discount/Premium-0.02% Administrator, Advisor and Custodian AdministratorSSgA Funds Management, Inc. AdvisorSSgA Funds Management, Inc. CustodianState Street Bank and Trust Company DistributorState Street Global Advisors Funds Distributors, LLC Transfer AgentState Street Bank and Trust Company TrusteeN/A Lead Market MakerVirtu Financial Options OptionableOptionable Options Volume84,766 Put Options62,166 Call Options22,600 Short Interest53,580,000 shs Miscellaneous Outstanding Shares76,700,000Beta0.97 Creation Unit50,000 Creation Fee$250.00 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Ad DTIthe most reliable asset on earth is making a comebackGlobal tensions have been pushing the price of gold to all time highs… Just recently, gold peaked at a record $2,000 (and is now closer to $2,200). And there’s something else critical at play right now in the world’s largest asset. Because of these critical factors, a lot of massive investment institutions are now pumping more money into gold. And as we speak, some are even calling for a massive rally in the precious metal.And you can see how it works for FREE when you Click Here SPDR S&P Biotech ETF ExpensesTypeXBIHealth Care ETFsEquity ETFsNYSEARCA ETFsAll ETFsManagement Fee0.35%0.57%0.54%0.50%0.51%Other Expenses0.00%0.40%0.54%0.64%0.58%Total Expense0.35%0.72%0.70%0.74%0.70%Fee Waiver0.00%-0.53%-0.54%-0.69%-0.56%Net Expense0.35%0.61%0.60%0.57%0.58% SPDR S&P Biotech ETF (XBI) Holdings & ExposureTop 10 XBI HoldingsBridgeBio Pharma(NASDAQ:BBIO)Holding Weight: 2.26%Revolution Medicines(NASDAQ:RVMD)Holding Weight: 1.45%Halozyme Therapeutics(NASDAQ:HALO)Holding Weight: 1.43%ACADIA Pharmaceuticals(NASDAQ:ACAD)Holding Weight: 1.33%Catalyst Pharmaceuticals(NASDAQ:CPRX)Holding Weight: 1.31%Novavax(NASDAQ:NVAX)Holding Weight: 1.27%Neurocrine Biosciences(NASDAQ:NBIX)Holding Weight: 1.26%AbbVie(NYSE:ABBV)Holding Weight: 1.22%Incyte(NASDAQ:INCY)Holding Weight: 1.22%Vertex Pharmaceuticals(NASDAQ:VRTX)Holding Weight: 1.21%XBI Sector ExposureXBI Industry ExposureFull Holdings Details Key ExecutivesJames E. Ross (Age 52)President, Trustee Peter A. Ambrosini (Age 69)Chief Compliance Officer Michael P. Riley (Age 44)Vice President Gary L. French (Age 64)Treasurer John W. Clark (Age 46)Assistant Treasurer Matthew W. Flaherty (Age 42)Assistant Treasurer Chad C. Hallett (Age 47)Assistant Treasurer of Street tracks series trust Mary Moran Zeven (Age 52)Secretary Scott M. Zoltowski (Age 44)Assistant Secretary Dave KellyIndependent TrusteeMore ExecutivesSimilar ETFsiShares Biotechnology ETFNASDAQ:IBBiShares U.S. Medical Devices ETFNYSEARCA:IHIiShares Global Healthcare ETFNYSEARCA:IXJiShares U.S. Healthcare ETFNYSEARCA:IYHFidelity MSCI Health Care Index ETFNYSEARCA:FHLCInstitutional OwnershipNomura Holdings Inc.Bought 79,500 shares on 3/27/2024Ownership: 0.000%PNC Financial Services Group Inc.Bought 2,834 shares on 3/22/2024Ownership: 0.106%Healthcare of Ontario Pension Plan Trust FundBought 635,000 shares on 3/21/2024Ownership: 3.137%Kingdon Capital Management L.L.C.Sold 210,000 shares on 3/18/2024Ownership: 0.000%B. Riley Wealth Advisors Inc.Sold 933 shares on 3/15/2024Ownership: 0.008%View All Institutional Transactions XBI ETF - Frequently Asked Questions How have XBI shares performed in 2024? SPDR S&P Biotech ETF's stock was trading at $89.29 on January 1st, 2024. Since then, XBI shares have increased by 7.0% and is now trading at $95.51. View the best growth stocks for 2024 here. What does XBI invest in? SPDR S&P Biotech ETF is a equity fund issued by SSgA. XBI focuses on health care investments and follows the S&P Biotech Index. The fund's investments total to approximately $7.54 billion assets under management. What stocks does SPDR S&P Biotech ETF hold? XBI invests in 139 holdings. Some of the stocks in their portfolio include BridgeBio Pharma (BBIO), Revolution Medicines (RVMD), Halozyme Therapeutics (HALO), ACADIA Pharmaceuticals (ACAD), Catalyst Pharmaceuticals (CPRX), Novavax (NVAX), Neurocrine Biosciences (NBIX), AbbVie (ABBV), Incyte (INCY) and Vertex Pharmaceuticals (VRTX). What is the management fee for SPDR S&P Biotech ETF? SPDR S&P Biotech ETF's management fee is 0.35% and has no other recorded expenses or fee waivers. The net expense ratio for XBI is 0.35%. What other stocks do shareholders of SPDR S&P Biotech ETF own? Based on aggregate information from My MarketBeat watchlists, some companies that other SPDR S&P Biotech ETF investors own include Intel (INTC), NVIDIA (NVDA), Pfizer (PFE), Gilead Sciences (GILD), iShares Biotechnology ETF (IBB), Walt Disney (DIS), Micron Technology (MU), Cisco Systems (CSCO), AbbVie (ABBV) and Netflix (NFLX). Who are SPDR S&P Biotech ETF's major shareholders? SPDR S&P Biotech ETF's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Citadel Advisors LLC (0.00%), Avoro Capital Advisors LLC (5.79%), Nantahala Capital Management LLC (0.00%), Goldman Sachs Group Inc. (0.00%), Healthcare of Ontario Pension Plan Trust Fund (3.14%) and Healthcare of Ontario Pension Plan Trust Fund (3.14%). How do I buy shares of SPDR S&P Biotech ETF? Shares of XBI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSEARCA:XBI) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersGrab Your Free Bitcoin Today!Crypto Swap ProfitsMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceTop Project Outperforms BTC in 2023…Crypto 101 MediaThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryMost important medical advance in 100 yearsThe Oxford ClubFed launches fourth dollar overhaulStansberry ResearchSHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SPDR S&P Biotech ETF Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.